These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26085639)

  • 1. Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease.
    Casali BT; Corona AW; Mariani MM; Karlo JC; Ghosal K; Landreth GE
    J Neurosci; 2015 Jun; 35(24):9173-81. PubMed ID: 26085639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer's disease.
    Casali BT; Reed-Geaghan EG; Landreth GE
    J Neuroinflammation; 2018 Feb; 15(1):43. PubMed ID: 29448961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
    Corona AW; Kodoma N; Casali BT; Landreth GE
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):61-72. PubMed ID: 26175148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
    Tai LM; Koster KP; Luo J; Lee SH; Wang YT; Collins NC; Ben Aissa M; Thatcher GRJ; LaDu MJ
    J Biol Chem; 2014 Oct; 289(44):30538-30555. PubMed ID: 25217640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
    Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE
    Science; 2012 Mar; 335(6075):1503-6. PubMed ID: 22323736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.
    Savage JC; Jay T; Goduni E; Quigley C; Mariani MM; Malm T; Ransohoff RM; Lamb BT; Landreth GE
    J Neurosci; 2015 Apr; 35(16):6532-43. PubMed ID: 25904803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.
    Mariani MM; Malm T; Lamb R; Jay TR; Neilson L; Casali B; Medarametla L; Landreth GE
    Sci Rep; 2017 Feb; 7():42270. PubMed ID: 28205585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease.
    Kawahara K; Suenobu M; Ohtsuka H; Kuniyasu A; Sugimoto Y; Nakagomi M; Fukasawa H; Shudo K; Nakayama H
    J Alzheimers Dis; 2014; 42(2):587-605. PubMed ID: 24916544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
    Fanaee-Danesh E; Gali CC; Tadic J; Zandl-Lang M; Carmen Kober A; Agujetas VR; de Dios C; Tam-Amersdorfer C; Stracke A; Albrecher NM; Manavalan APC; Reiter M; Sun Y; Colell A; Madeo F; Malle E; Panzenboeck U
    Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2224-2245. PubMed ID: 31055081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.
    Boehm-Cagan A; Michaelson DM
    J Neurosci; 2014 May; 34(21):7293-301. PubMed ID: 24849361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.
    Zhao J; Fu Y; Liu CC; Shinohara M; Nielsen HM; Dong Q; Kanekiyo T; Bu G
    J Biol Chem; 2014 Apr; 289(16):11282-11292. PubMed ID: 24599963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omega-3 Fatty Acid-Type Docosahexaenoic Acid Protects against Aβ-Mediated Mitochondrial Deficits and Pathomechanisms in Alzheimer's Disease-Related Animal Model.
    Park YH; Shin SJ; Kim HS; Hong SB; Kim S; Nam Y; Kim JJ; Lim K; Kim JS; Kim JI; Jeon SG; Moon M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Continuing Failure of Bexarotene in Alzheimer's Disease Mice.
    Balducci C; Paladini A; Micotti E; Tolomeo D; La Vitola P; Grigoli E; Richardson JC; Forloni G
    J Alzheimers Dis; 2015; 46(2):471-82. PubMed ID: 25777514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease.
    Lebbadi M; Julien C; Phivilay A; Tremblay C; Emond V; Kang JX; Calon F
    J Alzheimers Dis; 2011; 27(4):853-69. PubMed ID: 21914946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.
    Lefterov I; Schug J; Mounier A; Nam KN; Fitz NF; Koldamova R
    Neurobiol Dis; 2015 Oct; 82():132-140. PubMed ID: 26071899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.
    LaClair KD; Manaye KF; Lee DL; Allard JS; Savonenko AV; Troncoso JC; Wong PC
    Mol Neurodegener; 2013 Jun; 8():18. PubMed ID: 23764200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane lipid modifications and therapeutic effects mediated by hydroxydocosahexaenoic acid on Alzheimer's disease.
    Torres M; Price SL; Fiol-Deroque MA; Marcilla-Etxenike A; Ahyayauch H; Barceló-Coblijn G; Terés S; Katsouri L; Ordinas M; López DJ; Ibarguren M; Goñi FM; Busquets X; Vitorica J; Sastre M; Escribá PV
    Biochim Biophys Acta; 2014 Jun; 1838(6):1680-92. PubMed ID: 24374316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention.
    Ma QL; Teter B; Ubeda OJ; Morihara T; Dhoot D; Nyby MD; Tuck ML; Frautschy SA; Cole GM
    J Neurosci; 2007 Dec; 27(52):14299-307. PubMed ID: 18160637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study.
    Mirza Z; Beg MA
    Curr Alzheimer Res; 2017; 14(3):327-334. PubMed ID: 27842487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New hope from an old drug: fighting Alzheimer's disease with the cancer drug bexarotene (targretin)?
    Aicardi G
    Rejuvenation Res; 2013 Dec; 16(6):524-8. PubMed ID: 24047423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.